Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug:145:84-87.
doi: 10.1016/j.yjmcc.2020.06.007. Epub 2020 Jun 18.

Apelin-potential therapy for COVID-19?

Seyed Soheil Saeedi Saravi  1 , Jürg H Beer  2
Affiliations

Apelin-potential therapy for COVID-19?

Seyed Soheil Saeedi Saravi et al. J Mol Cell Cardiol. 2020 Aug.

Abstract

We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.

Keywords: Apelin; COVID-19; Renin-angiotensin system.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
The schematic of the hypothesis on the beneficial apelin-mediated down-regulation of renin-angiotensin system in COVID-19 disease.
See this image and copyright information in PMC

References

    1. Gu H., Xie Z., Li T., Zhang S., Lai C., Zhu P. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci. Rep. 2016;6 - PMC - PubMed
    1. Recombinant Human Angiotensin-Converting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19 (APN01-COVID-19) 2020. https://www.clinicaltrials.gov/ct2/show/NCT04335136
    1. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. J. Biol. Chem. 2000;275:33238–33243. - PubMed
    1. South A.M., Tomlinson L., Edmonston D., Hiremath S., Sparks M.A. Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic. Nat. Rev. Nephrol. 2020 doi: 10.1038/s41581-020-0279-4. - DOI - PMC - PubMed
    1. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020;17:259–260. - PMC - PubMed

MeSH terms